Envoplakin inhibitors are a class of chemical compounds designed to specifically target and inhibit the function of the envoplakin protein, a component of the epidermal cornified envelope. Envoplakin is a cytoskeletal linker protein that plays a critical role in the formation of the cornified envelope, a structure that reinforces the outer layer of the skin, providing mechanical resilience and protective functions. Envoplakin interacts with other proteins, such as periplakin and involucrin, and becomes crosslinked to membrane proteins during the final stages of keratinocyte differentiation, contributing to the structural integrity of the epidermis. Inhibition of envoplakin allows researchers to explore its role in these processes, particularly its involvement in maintaining the structural and mechanical properties of epithelial cells and tissues.
The molecular mechanisms by which envoplakin inhibitors function typically involve blocking the protein's ability to associate with other proteins in the cornified envelope or its role in crosslinking processes. These inhibitors may interfere with the interaction domains that allow envoplakin to bind to keratin filaments or other structural proteins, thereby preventing the proper assembly of the envelope. By inhibiting envoplakin, scientists can disrupt the formation and stability of the cornified envelope, providing insights into the molecular pathways responsible for skin barrier formation and cellular differentiation in the epidermis. Studying envoplakin inhibition also helps researchers understand how this protein contributes to cellular cohesion and resistance to mechanical stress in epithelial tissues, offering a deeper look into the structural organization and functions of the skin's outermost layers.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
By inhibiting dihydrofolate reductase, methotrexate can decrease DNA synthesis and subsequently reduce the transcription of genes such as envoplakin in proliferative tissues. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $76.00 $255.00 | 18 | |
Hydroxyurea impairs DNA replication by inhibiting ribonucleotide reductase, potentially causing a decrease in envoplakin transcription due to limited nucleotide availability. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Suberoylanilide Hydroxamic Acid changes the acetylation status of histones, which can lead to a condensed chromatin structure at the envoplakin locus, resulting in reduced transcription of the envoplakin gene. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
Fluorouracil disrupts RNA processing by incorporating into RNA, which can result in the premature termination of envoplakin mRNA elongation, decreasing its expression. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib blocks the degradation of ubiquitin-tagged proteins, which could lead to the accumulation of repressive transcription factors and subsequent reduction of envoplakin expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR complex 1, leading to the deactivation of S6K1 and 4E-BP1, which can result in decreased translation of mRNAs, including that of envoplakin. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide disrupts the transcription of specific genes by promoting the degradation of transcription factors, which might lead to decreased envoplakin mRNA levels. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $76.00 $82.00 $367.00 | 36 | |
Dexamethasone activates glucocorticoid receptors that can transrepress transcription factors involved in envoplakin expression, leading to its decreased synthesis in epidermal cells. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
Doxorubicin intercalates into DNA, and by inhibiting topoisomerase II, it can induce DNA damage responses that may downregulate envoplakin transcription as a stress response. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A, by inhibiting histone deacetylase, can increase histone acetylation and reduce the transcription of genes like envoplakin by affecting chromatin accessibility. |